A surge in thyroid storm deaths among those hospitalized with thyrotoxicosis was likely related to COVID-19, but other risk ...

KITE-363, a dual-targeting CAR T-cell therapy, shows a strong safety profile and high responses in patients who have highly ...

The agency set aside concerns about UroGen’s approval trial to greenlight mitomycin intravesical solution for recurrent non-muscle invasive bladder cancer.